APA (7th ed.) Citation

Schwebke, J. R., Sobel, R., Gersten, J. K., Sussman, S. A., Lederman, S. N., Jacobs, M. A., . . . Sobel, J. D. (2022). Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases, 74(11), 1979. https://doi.org/10.1093/cid/ciab750

Chicago Style (17th ed.) Citation

Schwebke, Jane R., et al. "Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)." Clinical Infectious Diseases 74, no. 11 (2022): 1979. https://doi.org/10.1093/cid/ciab750.

MLA (9th ed.) Citation

Schwebke, Jane R., et al. "Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)." Clinical Infectious Diseases, vol. 74, no. 11, 2022, p. 1979, https://doi.org/10.1093/cid/ciab750.